Exact Sciences Corp
EXAS
View Detailed Chart
101.519USD
+0.019+0.02%
Market hours （ET）Quotes delayed by 15 min
19.23BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.02%
5 Days
+0.45%
1 Month
+51.45%
6 Months
+89.68%
Year to Date
+80.67%
1 Year
+65.75%
View Detailed Chart
TradingKey Stock Score of Exact Sciences Corp
Currency: USD Updated: 2025-12-12Key Insights
Exact Sciences Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 16/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 98.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Exact Sciences Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
23
analysts
Hold
Current Rating
98.673
Target Price
-2.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Exact Sciences Corp Highlights
StrengthsRisks
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.37% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.76B.
Fairly Valued
The company’s latest PE is -19.01, at a medium 3-year percentile range.
Held by Invesco
Star Investor Invesco holds 176.61K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.52.
Exact Sciences Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Exact Sciences Corp Info
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Ticker SymbolEXAS
CompanyExact Sciences Corp
CEOConroy (Kevin T)
Websitehttps://www.exactsciences.com/
FAQs
What is the current price of Exact Sciences Corp (EXAS)?
The current price of Exact Sciences Corp (EXAS) is 101.519.
What is the symbol of Exact Sciences Corp?
The ticker symbol of Exact Sciences Corp is EXAS.
What is the 52-week high of Exact Sciences Corp?
The 52-week high of Exact Sciences Corp is 101.950.
What is the 52-week low of Exact Sciences Corp?
The 52-week low of Exact Sciences Corp is 38.812.
What is the market capitalization of Exact Sciences Corp?
The market capitalization of Exact Sciences Corp is 19.23B.
What is the net income of Exact Sciences Corp?
The net income of Exact Sciences Corp is -1.03B.
Is Exact Sciences Corp (EXAS) currently rated as Buy, Hold, or Sell?
According to analysts, Exact Sciences Corp (EXAS) has an overall rating of Hold, with a price target of 98.673.
What is the Earnings Per Share (EPS TTM) of Exact Sciences Corp (EXAS)?
The Earnings Per Share (EPS TTM) of Exact Sciences Corp (EXAS) is -5.340.
Related Instruments
+3.21%
+1.11%
+1.65%
+1.35%
+1.39%
-0.21%
+1.55%
+0.34%
+2.26%
+0.16%
-2.75%
-0.20%
+3.33%
+0.57%
+0.67%
+2.89%
+1.64%
0.00%
+1.26%
-0.15%Popular Symbols
